Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease

• Published in: Journal of Alzheimer's disease Vol. 64; no. 3; p. 751
• Main Authors: Bartos, Ales, Fialová, Lenka, Švarcová, Jana
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2018
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - blood; Alzheimer Disease - cerebrospinal fluid; Female; Humans; Immunoglobulin G - blood; Male; Middle Aged; Neurofilament Proteins - immunology; tau Proteins - cerebrospinal fluid; tau Proteins - immunology; autoantibody; tau proteins; Alzheimer’s disease; cytoskeleton; immunity; neurofilament proteins; serum
• ISSN: 1875-8908
• DOI: 10.3233/JAD-180039

Unlike antibodies against amyloid-β, little is known about serum antibodies to neuron-specific cytoskeletal proteins in patients with Alzheimer's disease (AD). We aimed to study IgG autoantibodies against tau protein, light (NFL) and heavy subunits (NFH) of neurofilaments in serum of AD patients and elderly controls and to explore the evolution of antineurocytoskeletal antibody levels over time. Antibodies against three targets (tau, NFL, and NFH) were measured using ELISA in 100 serum samples from 51 cognitively normal elderly controls and 49 patients with AD. Our primary cross-sectional design was further extended to monitor fluctuations over 1-2 years in a subset of individuals. The AD patients had lower levels of anti-tau antibodies (p = 0.03) and even lower anti-NFH antibodies (p = 0.005) than those in the control group at baseline. On the contrary, anti-NFL antibodies or total IgG concentrations in serum did not differ. All three antibodies remained stable in both groups except for a selective and significant anti-tau decline in AD patients (p = 0.03). The different responses to these antigens suggest some antibody selectivity in AD. The significant decline was observed for only serum anti-tau antibodies in AD patients over time and it corresponds to lower anti-tau levels in these patients. Our findings indicate a special feature of disease-relevant antigens and humoral autoimmunity in AD.